Organogenesis (NASDAQ:ORGO) Stock Price Expected to Rise, BTIG Research Analyst Says

Organogenesis (NASDAQ:ORGO) had its target price upped by research analysts at BTIG Research from $7.00 to $9.00 in a report issued on Thursday, Marketbeat.com reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price target points to a potential upside of 61.00% from the company’s current price.

Other equities analysts have also recently issued reports about the stock. Cantor Fitzgerald lifted their target price on shares of Organogenesis from $7.00 to $9.00 and gave the company an “overweight” rating in a report on Friday, August 8th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Organogenesis in a report on Thursday, November 13th. Finally, Wall Street Zen raised Organogenesis from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Organogenesis Stock Performance

Shares of Organogenesis stock opened at $5.59 on Thursday. The stock has a market capitalization of $709.43 million, a price-to-earnings ratio of -46.58 and a beta of 1.68. The business has a 50-day moving average of $4.62 and a 200 day moving average of $4.27. Organogenesis has a 12 month low of $2.61 and a 12 month high of $7.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 2.88.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.11. The company had revenue of $150.86 million for the quarter, compared to the consensus estimate of $134.10 million. Organogenesis had a positive return on equity of 4.01% and a negative net margin of 1.30%. Organogenesis has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Organogenesis will post -0.07 earnings per share for the current year.

Hedge Funds Weigh In On Organogenesis

A number of hedge funds have recently added to or reduced their stakes in ORGO. PharVision Advisers LLC acquired a new position in Organogenesis during the 3rd quarter valued at approximately $155,000. Quarry LP acquired a new position in shares of Organogenesis during the 3rd quarter valued at $25,000. First Light Asset Management LLC raised its position in Organogenesis by 10.6% in the third quarter. First Light Asset Management LLC now owns 7,497,911 shares of the company’s stock worth $31,641,000 after acquiring an additional 720,748 shares in the last quarter. Bank of America Corp DE lifted its stake in Organogenesis by 27.2% during the third quarter. Bank of America Corp DE now owns 611,685 shares of the company’s stock valued at $2,581,000 after purchasing an additional 130,875 shares during the last quarter. Finally, Creative Planning lifted its position in shares of Organogenesis by 8.2% during the 3rd quarter. Creative Planning now owns 38,279 shares of the company’s stock valued at $162,000 after acquiring an additional 2,887 shares during the last quarter. Institutional investors and hedge funds own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.